Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 11/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | MMP14 | P50281 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 7/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16494333 | 0.85 | ACHE (0.49) | ACHEDRD2DRD4ALDH1A1CYP2C9 | |
| SCHEMBL16494849 | 0.82 | NPC1 (0.52) | ACHEALDH1A1SMN1; SMN2 | |
| SCHEMBL16495073 | 0.80 | HRH3 (0.42) | ACHEDRD2DRD4ALDH1A1SMN1; SMN2 | |
| SCHEMBL16494376 | 0.80 | TAAR1 (0.55) | ACHESMN1; SMN2GAA | |
| SCHEMBL28003267 | 0.80 | DRD2 (0.50) | ACHEDRD2DRD4ALDH1A1CYP2C9 | |
| SCHEMBL23217086 | 0.80 | DRD2 (0.44) | ACHEDRD2DRD4ALDH1A1CYP2C9 | |
| SCHEMBL29868521 | 0.78 | MGLL (0.53) | ACHE | |
| SCHEMBL3172299 | 0.78 | MGLL (0.53) | ACHE | |
| SCHEMBL29868757 | 0.78 | MGLL (0.53) | ACHE | |
| SCHEMBL2401958 | 0.78 | MGLL (0.53) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2394990-A1 | INDOLINE DERIVATIVES | Kyoto University (JP) | 2011-12-14 | — | — | EP | disclosed |
| US-20110294850-A1 | INDOLINE DERIVATIVES | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294850-A1 | INDOLINE DERIVATIVES | BCHE, ACHE, INMT | ACHE 2/4885DRD2 289/4885DRD4 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.